Skip to main content

Aristo in CIS region

Because every person has a right to health!

Russia & CIS map

In 2020, after a three-year break, Aristo Pharma officially returned to the pharmaceutical markets of the CIS to carry out independent supplies and sales of medicines in the following countries: Azerbaijan, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan. The sales leader of Aristo Pharma product portfolio, the urological drug Blemaren®, was successfully launched in Uzbekistan, Belarus, Moldova and Kazakhstan. Also in 2020 the decision was made to add the Mongolian market here.

In 2021 new products were added to Aristo product portfolio in these countries – Aescusan®, Espa-Lipon® and Espa-Bastin®. During 2021 the active work was carried out to register and prepare launch of Blemaren® on the markets of Mongolia and Kyrgyzstan. In 2022 Blemaren® was exported to Mongolia and Kyrgyzstan.

The results of operations in the CIS region in 2022 are impressive: sales growth in the region made 42% to 2021; 7 new products launched; sales contracts with new distributors in Belarus, Kazakhstan and Moldova concluded; decision to open Aristo representative office in Kazakhstan taken.

2023 began with the launch of Aristo new product in Kazakhstan – Candisilk (rebranded version of vaginal cream Clotrimazole 2%, well-known and very popular in Russia) and new employees recruitment in Almaty, Shymkent and Astana.

In June the first serialized batches of Blemaren and Aescusan were delivered to Uzbekistan. In July a subsidiary of Aristo Pharma in Kazakhstan was registered - Aristo Pharma LLP. The launch of new drug Levothyroxine is scheduled for August in Georgia.

The process of new drugs registration for the Moldovan market has been initiated with a new partner. For September the second delivery of Blemaren® to Mongolia is planned, as well as export of Blemaren® to new distributors in Kazakhstan.

With the opening of new Aristo office in Kazakhstan, the sales in the market are expected to increase significantly and Kazakhstan to become the biggest Aristo market in the CIS. All in all, the sales growth in 2023 is forecasted at level of 20%.

Please read the instructions before use, be aware of contraindications
Go to top